Advancing Medical and Biotech Solutions
from Scientific Insight to Real-World Impact
I work across biotechnology, medical innovation, and applied scientific research. Over time, this has led me to build and operate several projects and companies that may appear unrelated on the surface: drug discovery, medical devices, and animal health products. In practice, they reflect a consistent approach: identifying unmet needs, applying scientific rigor, and turning ideas into tangible outcomes.
This website is designed to provide clarity for investors, partners, and potential acquirers about what I do, what I am focused on, and how to engage.
Ordered by current priority and time commitment
Portable, wearable emergency intervention device designed to improve outcomes in time-critical situations. Development is progressing with provisional patent protection in place.
Public details are intentionally limited. Technical documentation available under NDA for qualified parties.
Development of an Asparagine Endopeptidase (AEP) inhibitor for Alzheimer's disease. Currently in lead optimization stage with mechanistic and translational work supporting clinical development pathway.
Animal health and nutrition business, maintained with limited day-to-day involvement. Established operational framework supports ongoing activities.
Out-of-hospital cardiac arrest remains a leading cause of sudden death worldwide. Survival depends heavily on the speed, consistency, and quality of the initial intervention. Existing automated systems can be effective, but their size, weight, and setup requirements can limit real-world usability in constrained or mobile environments.
IP Note: A USPTO provisional patent application has been filed. Public information intentionally remains high-level. Technical documentation and detailed materials can be shared under NDA.
I have published analytical papers focused on forecasting clinical trial outcomes and regulatory decisions for publicly traded biotechnology companies. These analyses were published prior to relevant events and used to inform structured strategies.
Reported summary across published analyses with methodology available for review.
A comprehensive analysis of Cassava Sciences and Simufilam, examining the scientific foundation and clinical trial structure. The assessment assigned a probability of success between 0.00032% to 0.0034%, indicating a high statistical likelihood of failure.
Analysis estimating $5.21 price per share excluding current cash for Milestone Pharmaceuticals if Etripamil received FDA acceptance, with an estimated 80% probability of approval.
Follow-up analysis after MIST received a Complete Response Letter for CMC issues. The CRL addressed chemistry, manufacturing, and control concerns—not safety or efficacy—presenting a favorable risk-to-reward opportunity at approximately $0.80 per share.
Critical analysis of aTyr Pharma's Phase III study for efzofitimod in pulmonary sarcoidosis. Preclinical studies showed no statistically significant impact on granuloma formation. The analysis estimated 65% probability of Phase III failure with projected 72% stock decline upon failure.
Beyond investment analysis, I conduct primary research into disease mechanisms and therapeutic approaches. My work on Alzheimer's disease proposes a novel perspective centered on the C/EBPβ-AEP pathway.
This paper presents a new perspective on Alzheimer's Disease, challenging mainstream hypotheses while leveraging existing research. The work proposes focusing on the C/EBPβ-AEP pathway, which could potentially improve both AD and PD pathologies. It suggests a combination therapy between a lead compound targeting this pathway and a ketogenic diet.
Read Paper →Following this research direction, I have pursued drugs and therapies with mechanisms of action similar to AEP inhibitors. This work was presented at the 25th Annual Biotech in Europe Forum in Basel in 2025, where partnership opportunities were explored.
Watch Presentation at Biotech in Europe Forum 2025For investment or acquisition discussions, strategic partnerships, or scientific collaboration, please reach out using the form below or through any of the channels listed.
Confidential materials can be shared under NDA.